Eli Lilly and Company (NYSE: LLY) is projected to have the best earnings growth for the next 5 years, with BMO Capital reaffirming an ‘Outperform’ rating and a price target of $1,200 on January 14. The stock has a 16.36% upside potential, thanks to its solid leadership position in the obesity treatment space and beyond for 2026 and beyond.

BMO Capital highlights Eli Lilly and Company’s (NYSE: LLY) growth and certainty in the incretin business, with broadening access and the expected launch of orforglipron. The firm also notes the company’s strong presence in other disease areas like Lp(a), contributing to its long-term growth outlook.

Eli Lilly and Company (LLY) recently announced a partnership with NVIDIA to develop an AI co-innovation lab for pharmaceutical research, with plans to invest up to $1 billion over five years. The Indiana-based company, established in 1876, is dedicated to enhancing lives globally through its pharmaceutical discoveries and developments.

Read more at Yahoo Finance: BMO Reaffirms Eli Lilly and Company (LLY) as an Obesity Market Leader